Earnings
Retrophin, Inc. announced it will report fourth quarter and full year 2018 financial results on Tuesday, February 26, 2019 after the close of the U.S. financial markets.
Ultragenyx Pharmaceutical Inc. announced that it will host a conference call on Tuesday, February 19, 2019 at 5pm ET to discuss its financial results and corporate update for the fourth quarter and the year ended December 31, 2018.
Medtronic plc announced that it will report financial results for the third quarter of fiscal year 2019 on Tuesday, February 19 , 2019.
Despite having achieved a record net sales of $477 million driven by the success of its powerhouse medication Adcetris in 2018, as well as a 58 percent increase in sales during the fourth quarter in comparison to the previous year, Seattle Genetics stock fell as the results did not meet analysts’ expectations.
BioArctic AB to publish the company’s Full Year Report for the period January – December 2018 on Thursday, February 14, 2019 at 08:00 a.m. CET.
Thirteen of those were development programs, the remaining 25 research-stage. In September, the company indicated it was on a cost-cutting program, planning to save 1.5 billion euros this year. Of the programs it is dumping, the most prominent is a mid-phase drug for respiratory syncytial virus (RSV), ALX-0171.
Like many other big pharma companies, Eli Lilly & Co. reported a good 2018 with a less optimistic view of 2019. Fourth-quarter 2018 revenue grew by 5 percent, driven by newer drugs. Operating expenses also went up by a percentage point. Full-year 2018 revenue grew by 7 percent to $24.556 billion.
Suven Life Sciences Limited announced its Un-audited financial results for the quarter ended 31st December 2018.
Cash position of €207.2 million as of December 31, 2018, compared to €273.8 million as of December 31, 2017
Gilead Sciences reported earnings per share profits for the fourth quarter of $1.44 per share, below analysts’ expectations of $1.70.
PRESS RELEASES